Preoperative Metabolic Tumor Volume2.5 Associated with Early Systemic Metastasis in Resected Pancreatic Cancer: A Transcriptome-Wide Analysis
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: 18F-fluorodeoxyglucose-positron emission tomography (18F-FDG-PET) reflects biological aggressiveness and predicts prognoses in various tumors. Evaluating the oncologic significance of the preoperative metabolic phenotype might be necessary for planning the surgical strategy in resectable pancreatic cancers. Methods: From January 2010 to December 2015, a total of 93 patients with pathologic T3 (pT3) pancreatic cancer were included in this study. Clinicopathological parameters and PET parameters were evaluated, and transcriptome-wide analysis was performed to identify the oncologic impact and molecular landscape of the metabolic phenotype of resectable pancreatic cancers. Results: Preoperative metabolic tumor volume (MTV)2.5 was significantly higher in the pN1 group compared to the pN0 group (11.1±11.2 vs 6.5±7.8, p=0.031). Higher MTV2.5 values (MTV2.5 ≥4.5) were associated with multiple lymph node metastasis (p=0.003), and the lymph node ratio was also significantly higher in resected pT3 pancreatic cancer with MTV2.5 ≥4.5 compared to those with MTV2.5 <4.5 (0.12±0.13 vs 0.05±0.08, p=0.001). Disease-specific survival of patients with MTV2.5 <4.5 was better than that of patients with MTV2.5 ≥4.5 (mean, 28.8 months; 95% confidence interval [CI], 40.1 to 57.0 vs mean, 32.6 months; 95% CI, 25.5 to 39.7; p=0.026). Patients with MTV2.5 ≥4.5 who received postoperative adjuvant chemotherapy showed better survival outcomes than patients with MTV2.5 ≥4.5 who did not receive adjuvant treatment in resected pT3 pancreatic cancers (p<0.001). Transcriptome-wide analysis revealed that tumors with MTV2.5 ≥4.5 demonstrated significantly different expression of cancer-related genes reflecting aggressive tumor biology. Conclusions: Resectable pancreatic cancer with high MTV2.5 is not only associated with lymph node metastasis but also early systemic metastasis. The molecular background of resectable pancreatic cancer with high MTV2.5 may be associated with aggressive biologic behavior, which might need to be considered when managing resectable pancreatic cancers. Further study is mandatory
Abstract
Background/Aims: 18F-fluorodeoxyglucose-positron emission tomography (18F-FDG-PET) reflects biological aggressiveness and predicts prognoses in various tumors. Evaluating the oncologic significance of the preoperative metabolic phenotype might be necessary for planning the surgical strategy in resectable pancreatic cancers. Methods: From January 2010 to December 2015, a total of 93 patients with pathologic T3 (pT3) pancreatic cancer were included in this study. Clinicopathological parameters and PET parameters were evaluated, and transcriptome-wide analysis was performed to identify the oncologic impact and molecular landscape of the metabolic phenotype of resectable pancreatic cancers. Results: Preoperative metabolic tumor volume (MTV)2.5 was significantly higher in the pN1 group compared to the pN0 group (11.1±11.2 vs 6.5±7.8, p=0.031). Higher MTV2.5 values (MTV2.5 ≥4.5) were associated with multiple lymph node metastasis (p=0.003), and the lymph node ratio was also significantly higher in resected pT3 pancreatic cancer with MTV2.5 ≥4.5 compared to those with MTV2.5 <4.5 (0.12±0.13 vs 0.05±0.08, p=0.001). Disease-specific survival of patients with MTV2.5 <4.5 was better than that of patients with MTV2.5 ≥4.5 (mean, 28.8 months; 95% confidence interval [CI], 40.1 to 57.0 vs mean, 32.6 months; 95% CI, 25.5 to 39.7; p=0.026). Patients with MTV2.5 ≥4.5 who received postoperative adjuvant chemotherapy showed better survival outcomes than patients with MTV2.5 ≥4.5 who did not receive adjuvant treatment in resected pT3 pancreatic cancers (p<0.001). Transcriptome-wide analysis revealed that tumors with MTV2.5 ≥4.5 demonstrated significantly different expression of cancer-related genes reflecting aggressive tumor biology. Conclusions: Resectable pancreatic cancer with high MTV2.5 is not only associated with lymph node metastasis but also early systemic metastasis. The molecular background of resectable pancreatic cancer with high MTV2.5 may be associated with aggressive biologic behavior, which might need to be considered when managing resectable pancreatic cancers. Further study is mandatory
참고문헌 (20)
- Hsu PP, "Cancer cell metabolism : Warburg and beyond", Cell, 134, pp.703~707 (2008)
- Bares R, "F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer", Radiology, 192, pp.79~86 (1994)
- Lindholm P, "Influence of the blood glucose concentration on FDG uptake in cancer : a PET study", J Nucl Med, 34, pp.1~6 (1993)
- Czernin J, "Positron emission tomography scanning : current and future applications", Annu Rev Med, 53, pp.89~112 (2002)
- Kinkel K, "Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods(US, CT, MR imaging, PET) : a metaanalysis", Radiology, 224, pp.748~756 (2002)
- Ahn SJ, "Correlation between 18Ffluorodeoxyglucose positron emission tomography and pathologic differentiation in pancreatic cancer", Ann Nucl Med, 28, pp.430~435 (2014)
- Kubota K, "From tumor biology to clinical PET : a review of positron emission tomography(PET)in oncology", Ann Nucl Med, 15, pp.471~486 (2001)
- Torizuka T, "In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET", J Nucl Med, 36, pp.1811~1817 (1995)
- Chung HH, "Clinical impact of integrated PET", CT on the management of suspected cervical cancer recurrence, 2007, pp.104, 529~534
- Shinoto M, "Usefulness of 18Ffluorodeoxyglucose positron emission tomography as predictor of distant metastasis in preoperative carbon-ion radiotherapy for pancreatic cancer", Anticancer Res, 33, pp.5579~5584 (2013)
- Chong JU, "Clinically determined type of 18F-fluoro-2-deoxyglucose uptake as an alternative prognostic marker in resectable pancreatic cancer", PLoS One, 12, pp.e0172606~ (2017)
- Kang CM, "Preoperative volume-based PET parameter, MTV2.5, as a potential surrogate marker for tumor biology and recurrence in resected pancreatic cancer", Medicine (Baltimore), 95, pp.e2595~ (2016)
- Kang CM, "Maximum standard uptake value as a clinical biomarker for detecting loss of SMAD4 expression and early systemic tumor recurrence in resected left-sided pancreatic cancer", Medicine (Baltimore), 95, pp.e2595~ (2016)
- Allen PJ, "Multi-institutional validation study of the American Joint Commission on Cancer (8th Edition)changes for T and N staging in patients with pancreatic adenocarcinoma", Ann Surg, 265, pp.185~191 (2017)
- Rebhan M, "GeneCards : integrating information about genes, proteins and diseases", Trends Genet, 13, pp.163~ (1997)
- Stelzer G, "The GeneCards Suite : from gene data mining to disease genome sequence analyses", Curr Protoc Bioinformatics, 54, pp.1.30.1~1.30.33 (2016)
- Krzywinski M, "Circos : an information aesthetic for comparative genomics", Genome Res, 19, pp.1639~1645 (2009)
- Kim BK, "18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma", Cancer, 117, pp.4779~4787 (2011)
- Müller V, "Insights into minimal residual disease in cancer patients : implications for anti-cancer therapies", Eur J Cancer, 46, pp.1189~1197 (2010)
- Kostakoglu L, "18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma", J Nucl Med, 44, pp.224~239 (2003)